… rationale for developing demethylating agents for the treatment of these diseases, …
demethylating agents given at nonintensive doses, and studies investigating in vivo demethylating …

… Many of these agents are currently being tested in clinical … epigenetic drugs based on the
inhibition of DNA methylation. Combinatorial therapies that couple DNA demethylating agents …

… this treatment might result in a better selection of effective agents and in a more rapid
development. We divided compounds in demethylating agents … Epigenetic treatment is a reality in …

… That a substantial portion of patients benefited to some degree from such demethylating
agents, which are quite nonspecific, is somewhat surprising. There is clearly room to improve …

… alterations in cancer, and to subsequently develop new epigenetic therapies. This review
delineates the latest cancer epigenetic models, the recent discovery of hypomethylation agents …

During the last 10 years, three European phase II studies were performed to investigate the
treatment of elderly patients with myelodysplastic syndrome (MDS) with low-dose 5-aza-2′-…

… However, we do not know what effect prolonged demethylation and epigenetic activation …
Some investigators have raised the concern that the longer term use of demethylating agents …

… DNA methylation constitutes a major epigenetic regulatory mechanism for inactivating gene
… treatment of MDS. The activity of these agents has demonstrated that epigenetic treatment is …

… Demethylating agents seem to be more effective in … epigenetic regulation of cancer progression
via DNA methylation, effective treatment of solid malignancies with demethylating agents …

… It is often hypomethylated after treatment with demethylating agents, with some reports
demonstrating that this translates into an increased expression of the relevant protein and …